Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medexus Pharmaceuticals Inc
MEDXF
Primary Symbol:
T.MDP
Healthcare
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA...
. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(1961)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 16, 2023 5:07pm
RE:Ability to pay down 40 mil
Co. not telling us the whole story. Cash at June 30 was $15.8 mil US + pp financing of $7.4 mil US => $14.3 mil US shortfall to repay $37.5 mil US debt. No way they did $14.3 mil US cash flow in
...more
(39)
•••
Rockafellow2
X
View Profile
View Bullboard History
Post by
Rockafellow2
on Oct 06, 2023 2:49pm
Ability to pay down 40 mil
Is a remarkable achievement if it's all cash . They seem to be able to reduce debt considerably over a one year period so I give them credit due to the high interest rate. I understand from
...more
Xcyte Digital Corp. Releases "Xperience" Subscription Service
posted May 17, 2024 9:00am by
Xcyte Digital Corp.
-
|
"Xcyte anticipates growing the Xperience one-stop offering further with additional event technologies and supporting services, such as digital marketing and lead generation. We look forward to providing future updates as we execute upon this growth strategy ...read more
(195)
•••
Napcoo
X
View Profile
View Bullboard History
Comment by
Napcoo
on Oct 06, 2023 8:02am
RE:Prediction Alert!
Debt reduction?! 40 mln debentures due on October 16, the company issued new debt to replace old debt or issue new shares by diluting, the fundamental did not change, still heavy in debt
(39)
•••
Rockafellow2
X
View Profile
View Bullboard History
Post by
Rockafellow2
on Oct 05, 2023 4:20pm
Prediction Alert!
This will shoot up $7 bucks the day they announce debt reduction on Oct 16th ... not before. That's a week this coming Monday ... Get ready to fill your pockets. Imo
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 21, 2023 5:01pm
New Press Release - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
All director nominees reelected and all other company proposals approved by shareholdersToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 05, 2023 6:41pm
New Press Release - Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units
TORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP) (OTCQX: MEDXF), is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter (the “Underwriter”),...
read article.
(39)
•••
Rockafellow2
X
View Profile
View Bullboard History
Post by
Rockafellow2
on Sep 05, 2023 2:19pm
In the event we elect to do so ...
Sounds like 'a maybe' to me ... Why can't they just say, that is what we are going to do ... Maybe cancel the debt if we elect to do so ... Sounds fishy to me fokes!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 05, 2023 7:31am
New Press Release - Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an...
read article.
(2)
•••
ARP511
X
View Profile
View Bullboard History
Comment by
ARP511
on Aug 27, 2023 3:19pm
RE:RE:News coming soon?
Awaiting tow important news.. one from US FDA and one from Health Canada.. I am LONG, looking for SP of $6+
(2137)
•••
nozzpack
X
View Profile
View Bullboard History
Comment by
nozzpack
on Aug 23, 2023 1:17pm
RE:News coming soon?
Very strong volumes today....somethings on the way..
(2)
•••
ARP511
X
View Profile
View Bullboard History
Post by
ARP511
on Aug 22, 2023 4:33pm
News coming soon?
Much awaited news from Health Canada on topical antifungal product may be coming! Staying long, hope to see $4+ soon.
(2137)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 18, 2023 7:10am
Very Significant Development News
Medexus presents phase 3/4 study data for Ixinity 2023-08-17 17:41 ET - News Release Mr. Ken d'Entremont reports MEDEXUS STUDY SUPPORTS EFFICACY AND SAFETY OF
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 17, 2023 5:31pm
New Press Release - Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent safety profilePhase 3/4 data presentation follows FDA acceptance for review of IXINITY® supplemental Biological License...
read article.
(2)
•••
ARP511
X
View Profile
View Bullboard History
Comment by
ARP511
on Aug 17, 2023 11:52am
RE:Pure manipulation
Happy to see an uptrend..
(2)
•••
ARP511
X
View Profile
View Bullboard History
Post by
ARP511
on Aug 16, 2023 4:06pm
Pure manipulation
Someone is frantically trying to get the SP down drastically (not in line with market) and may know something. Folks, we are anticipating the approval of the nail laquer product from Health Canada
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Xcyte Digital Corp. Releases "Xperience" Subscription Service
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment